Tamrintamab pamozirine

N/A

Report date: 2024/02/05 14:07:27

Base Information

Drug NameTamrintamab pamozirine

Drug Alias NameSC-003

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SC-DR002 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDipeptidase 3 inhibitors

TargetsDipeptidase 3

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc Stemcentrx Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesStemcentrx Inc

Active IndicationsN/A

Inactive IndicationsOvarian Neoplasms

Other Information

ATC CodeN/A